BAX - NYSE
Baxter International Inc.
$18.54
-1.3%Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
At a Glance
Live SnapshotBaxter International Inc. Profit Bridge
Profitability Analysis
Gross Margin
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Baxter International Inc. Income Statement
BAX • NYSE
| Baxter International Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
11.2B | 10.6B | 10.4B | 10.1B | 12.1B | 11.7B | 11.4B | 11.1B | 10.6B | 10.2B | 10B | 10.7B | 9.4B | 13.9B | 13.9B | 12.8B | 12.6B | 12.3B | 11.3B | 10.4B | |
GROSS PROFIT | ||||||||||||||||||||
(7.9B) | (6.7B) | (6.2B) | (6.5B) | (7.4B) | (7.1B) | (6.6B) | (6.3B) | (6.1B) | (6B) | (5.8B) | (6.1B) | (5.3B) | (6.8B) | (6.8B) | (6.9B) | (6B) | (6.2B) | (5.7B) | (5.6B) | |
3.4B | 4B | 4.2B | 3.5B | 4.7B | 4.6B | 4.8B | 4.8B | 4.5B | 4.1B | 4.1B | 4.6B | 4.2B | 7.1B | 7B | 6B | 6.5B | 6.1B | 5.5B | 4.7B | |
OPERATING INCOME | ||||||||||||||||||||
(3.7B) | (4B) | (3.4B) | (6.4B) | (3.4B) | (3B) | (3B) | (3.2B) | (3.2B) | (3.4B) | (3.7B) | (3.9B) | (3.7B) | (4.3B) | (4.1B) | (3.8B) | (3.6B) | (3.6B) | (3.4B) | (2.9B) | |
(2.9B) | (3B) | (3B) | (3.1B) | (2.8B) | (2.5B) | (2.5B) | (2.6B) | (2.6B) | (2.7B) | (3.1B) | (3.3B) | (3.1B) | (3.3B) | (3.2B) | (2.9B) | (2.7B) | (2.7B) | (2.5B) | (2.3B) | |
(518M) | (590M) | (518M) | (450M) | (531M) | (521M) | (595M) | (654M) | (615M) | (646M) | (603M) | (610M) | (582M) | (1.1B) | (946M) | (915M) | (917M) | (868M) | (760M) | (614M) | |
-308M | 14M | 707M | -2.8B | 1.4B | 1.6B | 1.8B | 1.6B | 1.3B | 745M | 449M | 656M | 496M | 2.8B | 2.9B | 2.1B | 2.9B | 2.6B | 2.2B | 1.8B | |
PRE-TAX INCOME | ||||||||||||||||||||
(290M) | (408M) | (508M) | (413M) | (207M) | (153M) | (111M) | (93M) | (85M) | (89M) | (146M) | (167M) | (155M) | (113M) | (92M) | (115M) | (117M) | (148M) | (124M) | (101M) | |
-238M | -341M | -439M | -394M | -193M | -134M | -71M | -45M | -55M | -66M | -126M | -145M | -128M | -87M | -54M | -87M | -98M | -76M | -22M | -101M | |
(279M) | (413M) | -28M | (2.8B) | -6M | -19M | -141M | -99M | -56M | (0.0) | (0.0) | (0.0) | (0.0) | -51M | (0.0) | (0.0) | (0.0) | (0.0) | (70M) | (0.0) | |
-197M | -303M | -465M | -403M | -234M | -324M | -802M | 33M | -188M | 4.2B | -21M | -166M | -121M | 17M | -137M | -246M | -143M | -102M | -54M | -95M | |
-505M | -289M | 242M | -3.2B | 1.1B | 1.3B | 970M | 1.6B | 1.1B | 5B | 428M | 490M | 375M | 2.8B | 2.8B | 1.9B | 2.7B | 2.5B | 2.1B | 1.7B | |
NET INCOME | ||||||||||||||||||||
(395M) | (37M) | (61M) | -135M | (83M) | (182M) | -41M | (65M) | (491M) | -12M | (35M) | (33M) | (60M) | (555M) | (553M) | (463M) | (519M) | (437M) | (407M) | (348M) | |
-957M | -649M | 2.7B | -2.4B | 1.3B | 1.1B | 1B | 1.5B | 602M | 5B | 968M | 2.5B | 2B | 2.3B | 2.2B | 1.4B | 2.2B | 2B | 1.7B | 1.4B |
SEC Filings
BAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 08, 2026 | May 04, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 23, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 15, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 22, 2025 | December 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 |
Related Guides
Continue your BAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.